Plasma and urinary metabolites of efonidipine hydrochloride in man

Xenobiotica

Volumn 26, Issue 2, 1996, Pages 229-239

  Nakabeppu, H ^a   Asada, M ^a   Oda, T ^a   Shinozaki, Y ^b   Yajima, T ^c  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

^b ZERIA PHARMACEUTICAL CO LTD   (Japan)

^c Kaiyu Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EFONIDIPINE;

ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA; URINARY EXCRETION; URINE;

EID: 0029913361     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046703     Document Type: Article

References (25)

1. BERESFORD, A. P., MACRAE, P. V., and STOPHER, D. A., 1988, Metabolism of amlodipine in the rat and the dog: a species difference. Xenobiotica, 18, 169-182.
2. GROSSI, P., PELLEGATTI, M., VIGELLI, G., AYRTON, J., DUNCAN, B. A., EVANS, G. L., and MALTAS, J., 1992, Lacidipine metabolism in rat and dog: identification and synthesis of mam metabolites. Xenobiotica, 22, 899-916.
3. GUENGERICH, F. P., and MACDONALD, T. L., 1984, Chemical mechanisms of catalysis of cytochromes P-450: a unified view. Accounts of Chemical Research, 17, 9-16.
4. HIGUCHI, S., SASAKI, H., SHIOBARA, Y., and SADO, T., 1977, Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica, 7, 469-479.
5. HOFFMANN, K.-J., and WEIDOLF, L., 1985, Identification of felodipine metabolites in rat urine. Biomedical Mass Spectrometry, 12, 414-423.
6. KOBAYASI, H., OKUMURA, S., KOSAKA, Y., KOBAYASHI, S., INOUE, A., OKA, T., and NAKAMIZO, N., 1988, Identification of benedipine hydrochloride metabolites in rats and dogs. Arzneimittel-Forschung/Drug Research, 38, 1753-1756.
7. LINDEKE, B., and CHO, A. K., 1982, N-dealkylation and deamination. In Metabolic Basis of Detoxication: Metabolism of Functional Groups, edited by W. B. Jakoby, J. R. Bend and J. Caldwell (New York: Academic) pp. 105-126.
8. MASUDA, Y., TAKEGUCHI, M., ARAKAWA, C., SAKAI, T., HIBI, M., TANAKA, S., SHIGENOBU, K., and KASUYA, Y., 1990, Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Archives internationales de Pharmacodynamic et de Thérapie, 304, 247-264.
9. MEDENWALD, V. H., SCHLOßMANN, K., and WÜNSCHE, C., 1972, Strukturaufklärung der renalen Ausscheidungsprodukte von 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5- dicarbonsauredimethyl ester. Arzneimittel-Forschung/Drug Research, 22, 53-56.
10. MEYER, H., SCHERLING, D., and KARL, W., 1983, Nitrendipine: identification and synthesis of main metabolites. Arzneimittel-Forschung/Drug Research, 33, 1528-1534.
11. MEYER, H., WEHINGER, E., BOSSERT, F., and SCHERLING, D., 1983, Nimodipine: synthesis and metabolic pathway. Arzneimittel-Forschung/Drug Research, 33, 106-112.
12. NAKABEPPU, H., NAKAJIMA, A., KAMIKAWAJI, Y., and SHINOZAKI, Y., 1995, Identification of efonidipine hydrochloride metabolites in rats. Arzneimittel-Forschung/Drug Research, 45, 766-770.
13. NAKASHIMA, M., KANAMARU, M., UEMATSU, T., SATO, R., MIZUNO, A., NAGASHIMA, S., TAKIGUCHI, S., TANAKA, S., HIBI, M., SAITO, T., and YOSHIDA, Y., 1991, Pharmacokinetics and safety of NZ-105 in healthy volunteers: single-dose and multipole-dose studies. Japanese Journal of Clinical Pharmacology and Therapeutics, 22, 673-683.
14. OGAWA, N., MIZUNO, K., FUKUSHIMA, K., SUWA, T., and SATOU, T., 1993, Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog. Xenobiotica, 23, 747-759.
15. PARINOV, V. J., ODINEC, A. G., GILEV, A. P., DUBUR, G. J., MUCENIECE, D. H., OZOL, J. J., SHATZ, V. D., GAVARS, M. P., and VIGANTE, B, A., 1985, Pharmacokinetics and metabolism of ryodipine in rats. Arzneimittel-Forschung/Drug Research, 35, 808-813.
16. PARKER, S., and WEINSTOCK, J., 1973, Biotransformation of 1,4-dihydro-2,6-dimethyl-4-(2-trifluoromethylphenyl)-3,5-pyridine dicarboxylic acid diethyl ester. Journal of Medical Chemistry, 16, 34-37.
17. RUSH, W. R., ALEXANDER, O., HALL, D. J., CAIRNCROSS, L., DOW, R. J., and GRAHAM, D. J. G., 1986, The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica, 16, 341-349.
18. SCHERLING, D., KARL, W., AHR, G., AHR, H. J., and WEHINGER, E., 1988, Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man. Arzneimittel-Forschung/Drug Research, 38, 1105-1110.
19. SHINOZAKI, Y., HIMORI, Y., SANO, H., NAKABEPPU, H., ODA, T., ESUMI, Y., and SEKI, H., 1991a, Studies on the metabolic fate of NZ-105 (I): absorption, distribution, metabolism and excretion after a single administration to rats. Xenobiotic Metabolism and Disposition, 6, 919-932.
20. SHINOZAKI, Y., HIMORI, Y., SANO, H., NAKABEPPU, H., ODA, T., ESUMI, Y., and SEKI, H., 1991b, Studies on the metabolic fate of NZ-105 (III): absorption, metabolism and excretion in dogs and protein binding. Xenobiotic Metabolism and Disposition, 6, 945-953.
21. TAKAYAMA, K., IWASAWA, Y., SAITO, K., SHIRATORI, K., and OHTAWA, M., 1989, Metabolism of a new dihydropyridine calcium antagonist in rats and dogs. Xenobiotica, 19, 1407-1420.
22. TAMURA, T., SAIGUSA, A., and KOKUBUN, S., 1991. Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line. Naunyu-Schmiedeberg's Archives of Pharmacology, 343, 405-410.
23. TERASHITA, S., TOKUMA, Y., FUJIWARA, T., SHIOKAWA, Y., OKUMURA, K., and NOGUCHI, H., 1987, Metabolism of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. Xenobiotica, 17, 1415-1425.
24. WEIDOLF, L., BORG, K. O., and HOFFMANN, K.-J., 1984, Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica, 14, 657-666.
25. YEH, S. Y., 1990, N-depyridination and N-dedimethylaminoethylation of tripelennamine and pyrilamne in the rat. Drug Metabolism and Disposition, 18, 453-461.